Treatment Eligibility
ARE YOUR PATIENTS ELIGIBLE FOR KALYDECO®(ivacaftor)?
Please see the responsive mutations below:
Bold = Newly approved mutations. December 2020.
CFTR Mutations Responsive to KALYDECO Based on Clinical and/or In Vitro Data¹⁻³ | ||||
---|---|---|---|---|
A1067T | G1349D* | P67L* | S1159P | |
A120T | G178E | Q1291R | S1251N* | |
A234D | G178R* | Q237E | S1255P* | |
A349V | G194R | Q237H | S549N* | |
A455E* | G314E | Q359R | S549R* | |
D110E | G551D* | R1070Q | S589N* | |
D110H | G551S* | R1070W* | S737F | |
D1152H* | G576A | R1162L | S945L* | |
D1270N | G970D | R117C* | S977F* | |
D192G | H1375P | R117G | T1053I | |
D579G* | H939R | R117H* | T338I | |
D924N | I1027T | R117L | V1293G | |
E193K | I1139V | R117P | V232D | |
E56K | I148T | R1283M | V562I | |
E822K | I175V | R170H | V754M | |
E831X* | I807M | R347H* | W1282R | |
F1052V | K1060T | R347L | Y1014C | |
F1074L | L1480P | R352Q* | Y1032C | |
F311del | L206W* | R553Q | 2789+ 5G→A* |
|
F311L | L320V | R668C | 3272- 261→G* |
|
F508C | L967S | R74W | 3849+10kbC→T* | 3849+ 10kbC→T* |
F508C;S1251N† | F508C; S1251N† |
L997F | R75Q | 711+3A→G* |
G1069R | M152V | R792G | ||
G1244E* | M952I | R933G | ||
G1249R | M952T | S1159F |
*Clinical data exist for these mutations.1
†Complex/compound mutations where a single allele of the CFTR gene has multiple mutations; these exist independent of the presence of mutations on the other allele.1